114 related articles for article (PubMed ID: 34281758)
1. A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy.
Carella M; Stefoni V; Broccoli A; Argnani L; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e817-e819. PubMed ID: 34281758
[No Abstract] [Full Text] [Related]
2. Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.
Lauer EM; Waterhouse M; Braig M; Mutter J; Bleul S; Duque-Afonso J; Duyster J; Marks R; Reinacher PC; Prinz M; Illerhaus G; Finke J; Schorb E; Scherer F
Br J Haematol; 2020 Jul; 190(2):e110-e114. PubMed ID: 32452526
[No Abstract] [Full Text] [Related]
3. Complete Response of a Young Woman With MYD88
Pabon CM; Neff JL; Forns TE; Wang J
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e809-e812. PubMed ID: 32660904
[No Abstract] [Full Text] [Related]
4. Successful Rapid Oral Desensitization to Ibrutinib in a Patient With Severe Immediate Hypersensitivity Reaction.
Tsilimidos G; Horisberger A; Ribi C; Cairoli A; Stalder G
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):e745-e747. PubMed ID: 34158264
[No Abstract] [Full Text] [Related]
5. Waldenstrom Macroglobulinemia Manifesting as Acute Kidney Injury and Bing-Neel Syndrome With Excellent Response to Ibrutinib.
Jafri H; Khan I; Sidda A; Khan NAJ; Kheetan M; Griswold D; Pacioles T
J Investig Med High Impact Case Rep; 2021; 9():23247096211021228. PubMed ID: 34078157
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.
T Low J; B Peters K
CNS Oncol; 2020 Mar; 9(1):CNS51. PubMed ID: 32141313
[TBL] [Abstract][Full Text] [Related]
7. [Mantle cell lymphoma with central nervous system relapse successfully treated with nasogastric-tube administration of ibrutinib].
Okahashi N; Uchihara M; Hoshino E
Rinsho Ketsueki; 2020; 61(10):1508-1510. PubMed ID: 33162449
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib for the treatment of Bing-Neel syndrome, a complication of Waldenström macroglobulinemia: Patient case report.
Hartsell L; Janes A; Larck C; Park S; Arnall JR
J Oncol Pharm Pract; 2019 Sep; 25(6):1534-1539. PubMed ID: 30760164
[TBL] [Abstract][Full Text] [Related]
9. [Combination of ibrutinib and temozolomide for the treatment of newly diagnosed elderly primary central nervous system diffuse large B cell lymphoma: a case report].
Wang L; Li X; He YZ
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):482. PubMed ID: 32654461
[No Abstract] [Full Text] [Related]
10. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W
Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336
[TBL] [Abstract][Full Text] [Related]
11. Central Nervous System Post-transplant Lymphoproliferative Disorder: Response to Ibrutinib.
Kallam A; Hansen N; Bierman P
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e930-e933. PubMed ID: 32782203
[No Abstract] [Full Text] [Related]
12. Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.
Lewis KL; Chin CK; Manos K; Casey J; Hamad N; Crawford J; Ho SJ; Issa S; Grigg A; Wood P; Gandhi MK; Do B; Nastoupil L; Hawkes EA; Cheah CY
Br J Haematol; 2021 Mar; 192(6):1049-1053. PubMed ID: 32677095
[TBL] [Abstract][Full Text] [Related]
13. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
Renaud L; Bossard JB; Carpentier B; Terriou L; Cambier N; Chanteau G; Escure G; Tilmont R; Barbieux S; Wemeau M; Hieulle J; Boyle EM; Morschhauser F
Eur J Haematol; 2021 Sep; 107(3):370-373. PubMed ID: 34018260
[No Abstract] [Full Text] [Related]
14. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
Ran F; Liu Y; Wang C; Xu Z; Zhang Y; Liu Y; Zhao G; Ling Y
Eur J Med Chem; 2022 Feb; 229():114009. PubMed ID: 34839996
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL.
Chen TL; Harrington B; Truxall J; Wasmuth R; Prouty A; Sloan S; Lehman AM; Sampath D; Orlemans E; Baiocchi RA; Alinari L; Byrd JC; Woyach JA; Hertlein E
J Hematol Oncol; 2021 Feb; 14(1):36. PubMed ID: 33627156
[TBL] [Abstract][Full Text] [Related]
16. What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
Bravaccini S; Martinelli G; Cerchione C
Cell Transplant; 2020; 29():963689720950209. PubMed ID: 32907382
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Bing-Neel syndrome with first line sequential chemoimmunotherapy: A case report.
Gavriatopoulou M; Ntanasis-Stathopoulos I; Moulopoulos LA; Manaios A; Fotiou D; Eleutherakis-Papaiakovou E; Migkou M; Bourgioti C; Terpos E; Kastritis E; Dimopoulos MA
Medicine (Baltimore); 2019 Nov; 98(44):e17794. PubMed ID: 31689856
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic treatment with Ibrutinib attenuates imiquimod-induced psoriasis-like inflammation in mice through downregulation of oxidative and inflammatory mediators in neutrophils and dendritic cells.
Al-Harbi NO; Nadeem A; Ahmad SF; Bakheet SA; El-Sherbeeny AM; Ibrahim KE; Alzahrani KS; Al-Harbi MM; Mahmood HM; Alqahtani F; Attia SM; Alotaibi MR
Eur J Pharmacol; 2020 Jun; 877():173088. PubMed ID: 32234429
[TBL] [Abstract][Full Text] [Related]
19. Dramatic Efficacy of Ibrutinib in a Schnitzler Syndrome Case with Indolent Lymphoma.
Claves F; Siest R; Lefebvre C; Valmary-Degano S; Carras S
J Clin Immunol; 2021 Aug; 41(6):1380-1383. PubMed ID: 33871787
[No Abstract] [Full Text] [Related]
20. B-cell prolymphocytic leukaemia with a t(4;14) FGFR3/IGH translocation: response to ibrutinib.
George P; Brown A; Weinkove R
Pathology; 2020 Jun; 52(4):491-492. PubMed ID: 32349864
[No Abstract] [Full Text] [Related]
[Next] [New Search]
